Biosimilars of Monoclonal Antibodies 2016
DOI: 10.1002/9781118940648.ch12
|View full text |Cite
|
Sign up to set email alerts
|

Process Development

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 65 publications
0
2
0
Order By: Relevance
“…This column utilises the high affinity of the Fc region of mAbs with protein A ligand, yielding purities more than 98%. While this recovery is largely dependent on column loading conditions, these parameters can be optimised at bench scale before an engineering batch is performed (Stimple & Wood, 2017). The use of protein A chromatography had emerged alongside protein G during the start of the biologics industry.…”
Section: Downstream Processingmentioning
confidence: 99%
See 1 more Smart Citation
“…This column utilises the high affinity of the Fc region of mAbs with protein A ligand, yielding purities more than 98%. While this recovery is largely dependent on column loading conditions, these parameters can be optimised at bench scale before an engineering batch is performed (Stimple & Wood, 2017). The use of protein A chromatography had emerged alongside protein G during the start of the biologics industry.…”
Section: Downstream Processingmentioning
confidence: 99%
“…Pre-treatments to clarification have also been under development for a significant period. While the use of pre-treatments is far simpler to implement that continuous chromatography, there are many issues associated with mAb interaction and protein loss (Stimple & Wood, 2017). Due to the sensitivity of mAbs to salts, pH and coagulants present, adding flocculants may significantly reduce recoveries (Daniel Dixon, 2018).…”
Section: Single Use Technologymentioning
confidence: 99%